Any current/future new fundraising through debt or equity?

The company is contemplating some fundraising for high-value dream projects, including menthol, peppermint oil, and other CAPEX expansions like Dihydromyrcenol, Amber Fleur, and CST capacity expansion. No definitive quantum, amount, or mode (debt or equity) has been finalized yet; plans are under preparation. Historically, debt has been around 1x equity, and the company aims to keep debt levels prudent. Future fundraising details, including the amount and mix of debt and equity, will be communicated once blueprints are clear. The company emphasizes maintaining financial discipline and ensuring

Any current/future capex/capital investment/strategic investment?

The company has ongoing and planned capex, including expansion of key existing products and new products like Menthol, Peppermint oil, and Helvotalite, which have been successfully developed at pilot and lab scale. Average capex turnaround is about 14 to 18 months from conception to commercialization. There is potential for ensuing phases of capex expansion, for instance in the JV with Givaudan after the first phase. Future capex will be financed through a balanced mix of equity and debt. Management is contemplating fundraising to support high-value projects like menthol, peppermint oil, dihyd

Future growth expectations in sales/revenue/volumes?

For FY 2024-25, expected volume growth is about 15% to 18%. Revenue growth is anticipated around 10% to 12% despite some price contractions. EBITDA margins projected to sustain between 18% and 20%, with potential improvement of 0.5 basis points if freight cost issues ease. Long-term revenue growth driven primarily by volume growth, as bulk aroma chemical industry growth correlates with volume increases. Continuous focus on new product development (e.g., Menthol, Peppermint oil) and expansion via capex over 14-18 months timelines. Strategic capex funding through a balanced mix of equi

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a 10% to 12% growth in overall revenue for the fiscal year 2024-25. Volume growth is anticipated to be around 15% to 18%. Steady EBITDA margins are forecasted in the range of 18% to 20%, with a possibility of a slight improvement (~0.5 basis points) over FY 2023-24. Profit after tax (PAT) witnessed a significant increase to Rs 95 crores in FY 23-24, about 350% higher compared to previous years. Future margins could improve further if external challenges (like freight issues) normalize. Ongoing capex investments and expansion plans (including JV phases) suggest potential for

Privi Speci.Q4 FY24

Privi Speci. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,424P/E: 39.9Market Cap: ₹14.0K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

For FY 2024-25, expected volume growth is about 15% to 18%.
Revenue growth is anticipated around 10% to 12% despite some price contractions.
EBITDA margins projected to sustain between 18% and 20%, with potential improvement of 0.5 basis points if freight cost issues ease.
Long-term revenue growth driven primarily by volume growth, as bulk aroma chemical industry growth correlates with volume increases.
Continuous focus on new product development (e.g., Menthol, Peppermint oil) and expansion via capex over 14-18 months timelines.
Strategic capex funding through a balanced mix of equity and debt, with debt to EBITDA ratio managed conservatively (under 2.5x internally targeted).
Management confident of maintaining steady growth trajectory due to strong R&D, customer relationships, and market positioning.

Margin guidance

Category 3

The company expects a 10% to 12% growth in overall revenue for the fiscal year 2024-25.
Volume growth is anticipated to be around 15% to 18%.
Steady EBITDA margins are forecasted in the range of 18% to 20%, with a possibility of a slight improvement (~0.5 basis points) over FY 2023-24.
Profit after tax (PAT) witnessed a significant increase to Rs 95 crores in FY 23-24, about 350% higher compared to previous years.
Future margins could improve further if external challenges (like freight issues) normalize.
Ongoing capex investments and expansion plans (including JV phases) suggest potential for future margin improvements.
Succession planning and a younger management team are expected to drive efficiency and growth.
The company is working on innovative biotech and specialty chemical products aimed at sustaining long-term growth.

See what Privi Speci. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is contemplating some fundraising for high-value dream projects, including menthol, peppermint oil, and other CAPEX expansions like Dihydromyrcenol, Amber Fleur, and CST capacity expansion.
No definitive quantum, amount, or mode (debt or equity) has been finalized yet; plans are under preparation.
Historically, debt has been around 1x equity, and the company aims to keep debt levels prudent.
Future fundraising details, including the amount and mix of debt and equity, will be communicated once blueprints are clear.
The company emphasizes maintaining financial discipline and ensuring most financial parameters are balanced during new growth plans.
There is an expressed intent not to let debt exceed 1x equity typically, though exceptions happened due to capex timing delays.

Order book

The transcript from the Privi Speciality Chemicals Limited analysts/investors call on May 3, 2024 does not explicitly mention the current or expected order book or pending orders status. However, key insights related to demand and growth outlook include: - The company continues to experience resilient demand from customers despite industry challenges like geopolitical unrest and freight cost escalations. - Customers have stood by the company through various external curveballs, indicating ongoing and stable order support. - For FY 2024-25, Privi expects 10%-12% growth in overall revenue and about 15% volume growth, implying a healthy order flow. - New contract prices are mostly fixed for calendar year 2024, covering around 65% of revenues, showing confirmed orders at set prices. - The company is actively looking at growth opportunities and plans significant capex, suggesting confidence in a strong and growing order book going forward. No specific numeric details on order book or pending orders were disclosed.

See what Privi Speci. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has ongoing and planned capex, including expansion of key existing products and new products like Menthol, Peppermint oil, and Helvotalite, which have been successfully developed at pilot and lab scale.
Average capex turnaround is about 14 to 18 months from conception to commercialization.
There is potential for ensuing phases of capex expansion, for instance in the JV with Givaudan after the first phase.
Future capex will be financed through a balanced mix of equity and debt.
Management is contemplating fundraising to support high-value projects like menthol, peppermint oil, dihydromyrcenol, Amber Fleur, and CST capacity expansion.
Capex investments are aligned with the company’s growth mindset and sustainability goals.
For FY 24-25, expect investments to support volume growth of 15%-18% and revenue growth of 10%-12%.

Track Privi Speci. — get its next earnings analysis in your feed

How does Privi Speci. rank vs peers in ?

Pro feature

ThisPrivi Speci.

Rev 3Mar 3

See where Privi Speci. sits in See which companies these are, and every other name in the sector.Open rankings

What Privi Speci.'s management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Privi Speci. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Continue your research

What Privi Speci.'s management said in earlier quarters